Home » Human Osteosarcoma Circulating Tumor Cells - T25 Plated Cells
Human Osteosarcoma Circulating Tumor Cells - T25 Plated Cells
Catalog Number : 36049-50CTC-T25
Availability : In Stock
Price : $550.00
 

Related Products


  • Description
  • Publication
  • Documents

 Human Osteosarcoma Circulating Tumor Cells - T25 Plated Cells

Also Avaliable as:

Frozen Vial Cells $550.00 shipped with Dry-ice. Cat#36049-50CTC

T25 plated cells $550.00 shipped at room temperature. Cat# 36049-50CTC-T25

T75 plated cells $750.00 shipped at room temperature. Cat# 36049-50CTC-T75

120 Population doublings or up to 12 passages.

One million viable cells upon thawing of frozen cells, frozen vial of cells shipped in dry-ice.

This product would require pre-coated flasks with Human Osteosarcoma Circulating Tumor Cell Extra-cellular Matrix Cat# E36049-50CTC and Human Osteosarcoma Circulating Tumor Cell Media Cat# M36049-50CTC

Cell Cultures from single donors, 1000 different cell cultures available, please indicate which lots you require from the 1000 donors, or any subcategories of the cancer type at the time of order.  If you do not specify the subcategory, we will provide you the Human Osteosarcoma CTC, randomly from our inventory.

Source: Human Peripheral Blood

Positive Markers: Osteocalcin, 1GFBP3, Oct 4, Alkaline Phosphatase, CD133 (3-5%), Tumorgenicity, e-cadherin

For non-academic use please inquire for pricing.

 

Cells are only guaranteed with purchase of Celprogen Media and Celprogen Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.


1000 individual donors are fully characterized proprietary patient-derived xenografts (PDX) representing all major histotypes and capturing tumor diversity.

Subcutaneous, orthotopic and disseminated models.  Extensive molecular and pharmacological characterization as well as information on patients' pretreatment to help you select the most appropriate model.

Integrated approach: use the same PDX models and/or the corresponding cell line in 2D/3D screening assays and follow-up in vivo studies, identify biomarkers predicting tumor sensitivity for your compound.  PDX Model: PDX36049-50CTC

Individually tailored study designs: proof of concept, dose level and schedule optimization, combinations, biomarker identification, etc.